Literature DB >> 6421522

Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus.

N Miyasaka, T Nakamura, I J Russell, N Talal.   

Abstract

The ability of peripheral blood lymphocytes from patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and Sjogren's syndrome (SS) to produce interleukin 2 (IL-2) and respond to it in-vitro was examined. Phytohemagglutinin-stimulated lymphocytes from over half of the SLE patients exhibited a decreased ability to produce IL-2 while their concanavalin A-generated blast cells responded normally to exogenous IL-2. Lymphocytes from RA patients not only produced less IL-2 than normals (P less than 0.001), but also responded poorly to exogenous IL-2 (P = 0.011). These abnormalities did not correlate with the patient's age, sex, duration of disease, or disease activity. Production of and response to IL-2 was widely varied among patients with SS and not different from controls. The decreased response of RA lymphocytes to IL-2 may result from a smaller number of cell surface IL-2 receptors since IL-2 adsorption to RA cells was lower than to either SLE or normal cells. These data suggest that IL-2-related abnormalities may play a role in the disordered immunoregulation characteristic of RA and perhaps of SLE.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6421522     DOI: 10.1016/0090-1229(84)90195-8

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  45 in total

1.  Imbalance of CD4+ lymphocyte subsets in patients with mixed connective tissue disease.

Authors:  H Becker; A Langrock; K Federlin
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

Review 2.  Rheumatology.

Authors:  R A Asherson; R Cervera; D P D'Cruz; G R Hughes
Journal:  Postgrad Med J       Date:  1991-02       Impact factor: 2.401

3.  Anti-DNA idiotype- and anti-idiotype-specific T cell responses in patients with systemic lupus erythematosus and their first-degree relatives.

Authors:  S Mendlovic; R Segal; Y Shoenfeld; E Mozes
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

Review 4.  New therapeutic approaches to autoimmune disease.

Authors:  N Talal
Journal:  Springer Semin Immunopathol       Date:  1986

5.  Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis.

Authors:  G Semenzato; L M Bambara; D Biasi; A Frigo; F Vinante; B Zuppini; L Trentin; C Feruglio; M Chilosi; G Pizzolo
Journal:  J Clin Immunol       Date:  1988-11       Impact factor: 8.317

6.  Interleukin 2 inhibitor in synovial fluid.

Authors:  P Emery; K C Gentry; A Kelso; I R Mackay
Journal:  Clin Exp Immunol       Date:  1988-04       Impact factor: 4.330

7.  Spontaneous recovery of the decreased expression in vitro of interleukin 2 receptors in rheumatoid arthritis.

Authors:  C Plater-Zyberk; K A Rockett; R N Maini
Journal:  Clin Exp Immunol       Date:  1988-07       Impact factor: 4.330

8.  Modulation of the IL-2 production defect in vitro in Graves' disease.

Authors:  Z Eisenstein; E Engelsman; M Weiss; Y Kalechman; B Sredni
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

9.  Increased Ia expression, T lymphocyte subset abnormalities and autoimmunity in murine strains bearing the lpr gene.

Authors:  M J Dauphinée; N Talal
Journal:  Clin Exp Immunol       Date:  1984-10       Impact factor: 4.330

10.  Impaired T-cell activation in patients with systemic lupus erythematosus.

Authors:  S Sierakowski; E J Kucharz; R W Lightfoot; J S Goodwin
Journal:  J Clin Immunol       Date:  1989-11       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.